ABBISKO-B (02256) announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd., has received approval from China's National Medical Products Administration (NMPA) for the Investigational New Drug (IND) application of ABSK141, an oral, highly active, and selective small molecule KRAS G12D inhibitor. The drug is intended for the treatment of advanced solid tumor patients with KRAS G12D mutations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.